International Journal of Clinical Pharmacy

, Volume 40, Issue 6, pp 1474–1481 | Cite as

Impact of pharmacist interventions on clinical outcome and cost avoidance in a university teaching hospital

  • Jean-Pierre JourdanEmail author
  • Alexandra Muzard
  • Isabelle Goyer
  • Yann Ollivier
  • Youssef Oulkhouir
  • Patrick Henri
  • Jean-Jacques Parienti
  • Cécile Breuil
Research Article


Background A significant number of clinical pharmacy services have shown to improve in-hospital medication safety and patient outcome. Prescription review and pharmacist interventions are a fundamental part of hospital clinical pharmacy activities. In a context of restricted financial resources, proving the economic and clinical impact of this activity seems necessary. Objective The aim of this study was to assess the clinical impact on patient outcomes and economic benefit of prescription review by pharmacists. Setting 1624-bed tertiary French university teaching hospital. Method Prospective single center study evaluating prescriptions for which a pharmacist intervention was issued over a 6-month period. The clinical impact of every pharmacist intervention was evaluated by a multidisciplinary experts committee. Economic benefit was evaluated from the public health care system spending standpoint. Main outcome measures Number of avoided hospitalization days and associated public health care system cost-avoidance. Results Prescription review and interventions by pharmacists prevented 73 intensive care unit hospitalization days, 74 continuous monitoring unit hospitalization days and 66 days of conventional hospitalization. €252,294.00 in public health expenditure were thus prevented. For every Euro invested in the prescription review activity, €5.09 of public health spending were potentially saved. Conclusion Our study shows that prescription review and clinical pharmacists’ interventions had an impact on clinical outcomes which translated into prevented hospitalization days. Prescription optimization through pharmacist interventions allows significant health care cost savings which makes this service highly efficient.


Clinical pharmacy services France Health care costs Pharmacist Interventions Presciption review 



Authors want to thank all members of the expert committee Marie Baudon, Laure Champ Rigot, Delphine Claeys Jouenne, Nathalie Derache, Sophie Fedrizzi, Adeline Flatres, Claudine Hecquard, Jocelyn Michon, Marion Sassier, Laurence Thomas Bacheley and Valérie Hamon-Poupinel.


No specific funding was provided for the completion of the study.

Conflicts of interest

All authors declare that they have no conflict of interest either personally or financially.

Supplementary material

11096_2018_733_MOESM1_ESM.xlsx (13 kb)
Supplementary material 1 (XLSX 12 kb)
11096_2018_733_MOESM2_ESM.docx (29 kb)
Supplementary material 2 (DOCX 29 kb)


  1. 1.
    Leape LL, Brennan TA, Laird NAN, Ph D, Lawthers ANNG, Sc D, et al. The nature of adverse events in hospitalized patients—results of the harvard medical practice study II. New Engl J Med. 1991;324:377–84.CrossRefGoogle Scholar
  2. 2.
    Leape LL, Bates DW, Cullen DJ, Cooper J, Demonaco HJ, Gallivan T, et al. Systems analysis of adverse drug events. J Am Med Assoc. 1995;274:35–43.CrossRefGoogle Scholar
  3. 3.
    Bayley BK, Savitz LA, Maddalone T, Stoner SE, Hunt JS, Wells R. Evaluation of patient care interventions and recommendations by a transitional care pharmacist. Ther Clin Risk Manag. 2007;3:695–703.Google Scholar
  4. 4.
    Cohen MM, Kimmel NL, Benage MK, Cox MJ, Sanders N, Spence D, et al. Medication safety program reduces adverse drug events in a community hospital. Qual Saf Health Care. 2005;14:169–74.CrossRefGoogle Scholar
  5. 5.
    Haavik S, Soeviknes S, Erdal H, Kjonniksen I, Berit Guttormsen A, Gerd Granas A. Prescriptions from general practitioners and in hospital physicians requiring pharmacists’ interventions. Pharmacoepidemiol Drug Saf. 2011;20:50–6.CrossRefGoogle Scholar
  6. 6.
    Rommers MK, Teepe-Twiss IM, Guchelaar H-J. Preventing adverse drug events in hospital practice: an overview. Pharmacoepidemiol Drug Saf. 2007;16:1129–35.CrossRefGoogle Scholar
  7. 7.
    Lazarou J, Pomeranz B, Corey P. Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. J Am Med Assoc. 1998;279:1200–5.CrossRefGoogle Scholar
  8. 8.
    Bond CA, Raehl CL. Adverse drug reactions in United States hospitals. Pharmacotherapy. 2006;26:601–8.CrossRefGoogle Scholar
  9. 9.
    Direction de la recherche, des études, de l’évaluation et des statistiques (DREES). Enquête Nationale sur les Evènements Indésirables graves associés aux Soins - Description des résultats (2009) In: Rapport final. 2011. Accessed 10 Jan 2018.
  10. 10.
    Direction de la recherche, des études, de l’évaluation et des statistiques (DREES). Enquêtes Nationales sur les Evènements Indésirables graves associés aux Soins - Comparaison des deux études ENEIS 2004 et (2009). In: Rapport final. 2011. Accessed 10 Jan 2018.
  11. 11.
    Direction de la recherche, des études, de l’évaluation et des statistiques (DREES). Les événements indésirables graves liés aux soins observés dans les établissements de santé: premiers résultats d’une étude nationale. In: Études et Résultats. 2005. Accessed 10 Jan 2018.
  12. 12.
    Samp JC, Touchette DR, Marinac JS, Kuo GM. Economic evaluation of the impact of medication errors reported by U.S. clinical pharmacists. Pharmacotherapy. 2014;34:350–7.CrossRefGoogle Scholar
  13. 13.
    Tasaka Y, Yasunaga D, Tanaka M, Tanaka A, Asakawa T, Horio I, et al. Economic and safety benefits of pharmaceutical interventions by community and hospital pharmacists in Japan. Int J Clin Pharm. 2016;38:321–9 (Springer Netherlands).CrossRefGoogle Scholar
  14. 14.
    Bond CA, Raehl CL. Clinical pharmacy services, pharmacy staffing, and hospital mortality rates. Pharmacotherapy. 2007;27:481–93.CrossRefGoogle Scholar
  15. 15.
    Blagburn J, Kelly-fatemi B, Akhter N, Husband A. Person-centred pharmaceutical care reduces emergency readmissions. Eur J Hosp Pharm. 2016;2(23):80–5.CrossRefGoogle Scholar
  16. 16.
    Hatoum HT, Hutchinson RA, Witte KW, Newby GP. Evaluation of the contribution of clinical pharmacists: inpatient care and cost reduction. Drug Intell Clin Pharm. 1988;22:252–9.CrossRefGoogle Scholar
  17. 17.
    Quffa LH, Panna M, Kaufmann MR, McKillop M, Dietrich NM, Franck AJ. Impact of a pharmacy-cardiology collaborative practice on dofetilide safety monitoring. Ann Pharmacother. 2016;1(51):39–43.Google Scholar
  18. 18.
    Klopotowska JE, Wierenga PC, de Rooij SE, Stuijt CC, Arisz L, Kuks PF, et al. The effect of an active on-ward participation of hospital pharmacists in Internal Medicine teams on preventable Adverse Drug Events in elderly inpatients: protocol of the WINGS study (Ward-oriented pharmacy in newly admitted geriatric seniors). BMC Health Serv Res. 2011;11:124 (BioMed Central Ltd.).CrossRefGoogle Scholar
  19. 19.
    Han JM, Ah YM, Suh SY, Jung SH, Hahn HJ, Im SA, et al. Clinical and economic impact of pharmacists’ intervention in a large volume chemotherapy preparation unit. Int J Clin Pharm. 2016;38:1124–32 (Springer International Publishing).CrossRefGoogle Scholar
  20. 20.
    Geurts MME, Stewart RE, Brouwers JRBJ. Implications of a clinical medication review and a pharmaceutical care plan of polypharmacy patients with a cardiovascular disorder. Int J Clin Pharm. 2016;38:808–15 (Springer International Publishing).CrossRefGoogle Scholar
  21. 21.
    Lucca JM, Ramesh M, Narahari GM, Minaz N. Impact of clinical pharmacist interventions on the cost of drug therapy in intensive care units of a tertiary care teaching hospital. J Pharmacol Pharmacother. 2012;3:242–7.CrossRefGoogle Scholar
  22. 22.
    Laekeman G, Simoens S, Buffels J, Gillard M, Robillard T, Benedetti MS, et al. Continuous versus on-demand pharmacotherapy of allergic rhinitis: Evidence and practice. Respir Med CME. 2011;4:51–9 (Elsevier Ltd.).CrossRefGoogle Scholar
  23. 23.
    Messerli M, Blozik E, Vriends N, Hersberger KE. Impact of a community pharmacist-led medication review on medicines use in patients on polypharmacy—a prospective randomised controlled trial. BMC Health Serv Res. 2016;16(145):1–16.Google Scholar
  24. 24.
    Kimberly JR, De Pouvourville G, D’Aunno T. The globalization of managerial innovation in health care. Cambridge University Press. 2008.Google Scholar
  25. 25.
    Les chiffres-clés - CHU de Caen. (2017). Accessed 10 Jan 2018.
  26. 26.
    Allenet B, Bedouch P, Rose FX, Escofier L, Roubille R, Charpiat B, et al. Validation of an instrument for the documentation of clinical pharmacists’ interventions. Pharm World Sci. 2006;28:181–8.CrossRefGoogle Scholar
  27. 27.
    Chedru V, Juste M. Evaluation médicale de l’impact clinique des interventions pharmaceutiques. J Pharm Clin. 1997;16:254–8.Google Scholar
  28. 28.
    Bordet R, Gautier S, Le Louet H, Dupuis B, Caron J. Analysis of the direct cost of adverse drug reactions in hospitalised patients. Eur J Clin Pharmacol. 2001;56:935–41.CrossRefGoogle Scholar
  29. 29.
    Apretna E, Haramburu F, Taboulet F, Bégaud B. Medical and socio-economical impact of drug-induced adverse reactions. Press Med. 2005;34:271–6.CrossRefGoogle Scholar
  30. 30.
    Bates DW, Cullen DJ, Laird N, Petersen LA, Small SD, Servi D, et al. Incidence of adverse drug events and potential adverse drug events. Implications for prevention. J Am Med Assoc. 1995;274:29–34 (ADE Prevention Study Group).CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2018

Authors and Affiliations

  1. 1.Department of PharmacyCaen UHCCaenFrance
  2. 2.Centre d’Etudes et de Recherche sur le Médicament de NormandieNormandie University, UNICAEN, CERMNCaenFrance
  3. 3.Department of Internal MedicineCaen UHCCaenFrance
  4. 4.Department of Chest MedicineCaen UHCCaenFrance
  5. 5.Renal Disease Teaching CenterCaen UHCCaenFrance
  6. 6.Clinical Research and Innovation DivisionCaen UHCCaenFrance

Personalised recommendations